In a long-standing war between an East Coast and a West Coast firm over erythropoietin (EPO) patents, Transkaryotic Therapies Inc. lost a battle on its home turf to Amgen Inc. when a federal judge upheld four of Amgen's claims, ruling that the company's patents are valid and have been infringed by TKT. (BioWorld Today)